TMEM214 Knockout cell line (ARPE-19)

CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.

TMEM214 (transmembrane protein 214) encodes a transmembrane protein predicted to participate in apoptotic processes. The protein is localized to multiple cellular compartments, including the Golgi apparatus, cytoplasmic microtubules, and endoplasmic reticulum, suggesting a role in cellular organization and regulation of cell death-related pathways.

The ARPE-19 cell line is a spontaneously arising human retinal pigment epithelial (RPE) cell line established in 1986 by Amy Aotaki-Keen from the normal eyes of a 19-year-old male donor. The cells exhibit characteristic RPE morphology, including the ability to form cobblestone-like monolayers and develop pigmentation during long-term culture. ARPE-19 provides a widely used in vitro model for studying retinal pigment epithelium biology, retinal function, ocular disease mechanisms, and cellular responses relevant to vision research.

Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.